Patients 70 years or older with acute myeloid leukemia (AML) have a poor prognosis. Recent studies suggested that intensive AML-type therapy is tolerated and may benefit most. We analyzed 446 patients 70 years or older with AML (≥ 20% blasts) treated with cytarabine-based intensive chemotherapy between 1990 and 2008, to identify risk groups for high induction (8-week) mortality. Excluding patients with favorable karyotypes, the overall CR rate was 45%, 4-week mortality 26%, and 8-week mortality 36%. The median survival was 4.6 months, and the one-year survival rate 28%. Survival was similar among patients treated before 2000 and since 2000. A multivariate analysis of prognostic factors for 8-week mortality identified the following to be independently adverse: age > 80 years, complex karyotypes, (≥ 3 abnormalities), poor performance (2-4 ECOG), and elevated creatinine >1.3 mg %. Patients with none, (28%), 1 (40%), 2 (23%), or ≥ 3 factors (9%) had estimated 8-week mortality rates of 16%, 31%, 55% and 71% respectively. The 8-week mortality model also predicted for differences in CR and survival rates. In summary, the prognosis of most patients (72%) aged 70 years or older with AML is poor with intensive chemotherapy (8-week mortality; median survival < 6 months).
INTRODUCTION
In patients with acute myeloid leukemia (AML), intensive chemotherapy combinations with different dose schedules of cytarabine and anthracycline result in complete response (CR) rates of 40% to 80% and in cure rates of 5% to 60%, depending on the patient and disease characteristics including age, performance status, cytogenetic abnormalities in the leukemic cells, molecular abnormalities, and organ functions. was developed (to demonstrate its added independent prognostic effect, but to allow for a risk model applicable to general practice).
The primary aim was to identify patients at high risk of 8-week mortality with intensive chemotherapy. A mortality of 30% or more with intensive chemotherapy could be used as a cautionary signal for physicians and patients to decide on whether the risk: benefit is worthwhile, or whether they may prefer investigational lower intensity therapies.
STUDY GROUP AND METHODS

Study Group
Adults with a diagnosis of AML who were 70 years or older, treated on frontline cytarabine-based intensive chemotherapy regimens from 1990 until 2008 were evaluated. For this analysis, AML was defined by the presence of 
Response criteria and Statistical Methods
Response criteria were as previously established.(6) A complete response (CR) required normalization of bone marrow morphology with 5% or less blasts, and of peripheral counts with granulocytes 10 9 /L or above and platelets 100 x 10 9 /L or above.
Induction mortality was defined by the 8-week mortality, since this was the time when the weekly mortality rate was reduced from the high initial rates to the lower rates noted during maintenance. It is also a measure of the combined effect of treatment-associated mortality and of mortality due to ineffective therapy that allows for persistence of disease and cytopenias. This definition avoids subjectivity in attributing mortality to therapy versus leukemia. In addition we reported a 4-week mortality, which is used in many published series, for the purpose of comparisons.
Differences among variables were compared by the Chi-squared tests. Table 2 .
Among 16 patients with Core Binding Factor (CBF) leukemia, 13 had inversion 16, and 3 had t(8;21). Overall, 10 achieved CR (63%). (Table 3 ). The median CR duration was 12 months. The median survival was 15 months; the 2-year survival rate was 18% ( Figure 1 ).
Outcome of the remaining 430 patients was then analyzed. Response to intensive chemotherapy is shown in Table 3 . Overall, 193 patients achieved CR (45%), and 154 (36%) died during remission induction (8-week mortality).
Among the 193 patients achieving CR, 183 (95%) achieved CR after 1 course, 9 after 2 courses, and 1 after 3 courses. The survival of patients was not different among patients achieving CR after 1 course or more than 1 course, considering the small numbers of patients in the latter category. The median CR duration was 10.8 months and the median survival in patients achieving CR was 13.8 months ( Figure 2 ). The median survival of the total study group (n=430) was 4.6 months (95% CI 3.9 to 6.0). The one-, two-and three-year survival rates were 28%, 16%, and 10% respectively ( Figure 3 ). The CR rates were 49% in patients treated before 2000 and 38% in patients treated since 2000. The median survivals were not different in the two decades ( Figure 3 ).
Prognostic factors associated with response, 8-week mortality and survival Table 4 details response, 8-week mortality, and survival by pretreatment characteristics.
Since the primary objective of this analysis is to identify risk events for high mortality with intensive chemotherapy, we conducted first a multivariate analysis of prognostic factors associated with 8-week mortality. This identified the following to have independent adverse significance: older age ≥ 80 years, poor performance status (ECOG 2-4), complex karyotype (≥ 3 abnormalities regardless of the presence or absence of chromosome 5 or 7 abnormalities), and creatinine > 1.3 mg/dL. (Table 5 ) Patients could be predicted to have 8-week low mortality rate (estimated 8-week mortality < 20%; 28% of patients; no adverse factors), intermediate mortality rate (estimated 8-week mortality 31%; 40% of patients; 1 adverse factor) and higher mortality rate (estimated 8-week mortality > 50%; 32% of patients; > 2 adverse factors). Since our previous study had shown consistent adverse factors predictive of mortality, CR and survival,(20) we applied the 8-week mortality risk model for prediction of CR and survival. As shown in Table 5 , the risk model for mortality was very predictive for differences in CR rates and for survival. (Figure 4 ). Separate multivariate analyses conducted for CR and survival identified the same 3 factors (poor performance, complex karyotype, creatinine >1.3 mg/dL) as independently adverse for CR (others identified were AHD ≥ 12 months, prior chemotherapy for other cancers, and high LDH), and for survival (others identified were older age [as for mortality], prior chemotherapy for other malignancy, elevated LDH, and lower albumin levels (Appendix A: Tables 1 and 2) The inclusion of the LAFR after accounting for the other independent prognostic factors identified LAFR to remain an independent favorable factor associated with a reduction of 8-week induction mortality (hazard ratio 0.35; p<0.001), improvement of the CR rate (odds ratio 3.09; p<0.001), and improvement of survival (hazard ratio 0.6; p<0.001).
Validation of the 8-week mortality Risk Model achieved CR. The median survival was 3.3 months, and 2-year survival rate 3%, significantly worse than the survival of patients treated since 1990, thus justifying the restriction of this study to the more modern era.
However, for the purpose of this model validation, the application of the proposed risk model to this independent study group provided validation of the risk model in an independent study group (Table 6 ; p=0.03).
DISCUSSION
In a review of the Surveillance, Epidemiology and End Results (SEER) data in elderly AML (19,42), among 3439 patients aged > 65 years analyzed (1991 -1996) , the median survival was only 2.4 months and the 2-year survival rate 6%. Only 34% of patients received chemotherapy during their course.
While the cost of therapy was 3 times higher with chemotherapy, the median survival of such patients was longer.
Recent studies suggested that intensive chemotherapy may be well tolerated in most elderly patients with AML, and implied that it might improve their prognosis.(8,43) The Food and Drug Administration and many AML experts consider intensive chemotherapy (3+7 regimens) as an acceptable standard of care against which novel investigational strategies would be compared. An editorial by C. Schiffer (44) also suggested that older patients with AML tolerated intensive chemotherapy well, with an estimated mortality of less than 10%, and that many may benefit from intensive chemotherapy.
Our single institutional experience using intensive chemotherapy in patients 70 years and older with AML demonstrated that, despite the achievement of reasonable CR rates, 40-50%, the overall survival of these patients remained poor, with a median survival of 4.6 months. This outcome was unchanged over the past two decades despite variations in intensive chemotherapy and improvements in supportive care measures. The 8-week mortality of 36% in our study group was prohibitively high.
An important question is whether there are subsets of patients 70 years or older in whom the benefit from intensive chemotherapy would outweigh the risks. These would be, for example, patients who may have an estimated 8-week mortality of less than 20%, a CR rate of more than 50%, and a 3-year survival rate of more than 10%. This appears to hold true for the uncommon subset of favorable karyotypic leukemias (CBF; 3.5% of total study group).
Among the remaining patients the multivariate analysis identified consistent adverse prognostic factors for 8-week mortality: age > 80 years, complex karyotype (≥ 3 abnormalities), poor performance (ECOG 2-4), and creatinine > To allow for the proposed risk model to be universally applicable, we did not include LAFR as a factor in the risk model. However, LAFR remained an independent favorable risk factor for reducing the risk of 8-week mortality after accounting for the other independent adverse factor (hazard ratio 0.35; p<0.001).
This suggests that the use of intensive supportive measures (reverse isolation, with intensive chemotherapy. Most would probably agree that an 8-week mortality of less than 10% to 20% to achieve a CR rate of more than 40% and a 3-year survival of more than 10% would be an acceptable benefit: risk ratio with intensive chemotherapy. This is the case, in our study, for patients with CBF leukemia and those with none of the 4 independent adverse factors. Most would also probably agree that an 8-week mortality rate of more than 30% and/or a 3-year survival rate of less than 10% with intensive chemotherapy is prohibitive.
Arguments may be offered for or against intensive chemotherapy for patients whose risks and benefits are between these two extremes (for example patients with an estimated 8-week modality of 10% to 30% and an estimated 3-year survival rate above 10%)
In summary, our analysis suggested that while intensive chemotherapy can be delivered to older patients (age ≥ 70 years) with AML, it may not be beneficial to most, and could be harmful to some. Excluding older patients with CBF leukemias and those without any of the 4 identified adverse risk factors for 8-week mortality (age < 80 years and performance 0-1 and non-complex karyotype and creatinine ≤ 1.3 mg %; 28% of patients), all others may be considered for investigational low-intensity strategies, or can be offered trials comparing intensive versus low-intensity therapies. 
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